Marc Bonten earned his MD (1991) and PhD (“the role of colonization of the upper intestinal tract in the pathogenesis of ventilator-associated pneumonia, 1994) at the Maastricht University Medical School, the Netherlands. He registered as internist in 2000, as infectious disease specialist in 2002 and as clinical microbiologist in 2008, all at the University Medical Center Utrecht, the Netherlands. From 2008 till March 2021 he was head of the Department of Medical Microbiology. Since 2003 he is head of the research group of Infectious Disease Epidemiology of the Julius Center of Health Sciences and Primary Care and professor of molecular epidemiology of infectious diseases. He has been a principal investigator in many large scale epidemiologic studies and investigator-initiated randomized trials of prevention and treatment of infectious diseases. His experience covers the full range of epidemiologic study designs including clinical trials, cohorts, case-control studies and mathematical modelling to study antibiotic resistance and infection prevention. Specific research interests include the epidemiology of antibiotic-resistant bacteria such as VRE, MRSA and MDR Enterobacteriaceae, selective decontamination in intensive care unit patients, prevention of ventilator-associated pneumonia, treatment of community-acquired pneumonia, and prevention and treatment of community-acquired pneumonia, including COVID-19.

He is chairman of the strategic research program Infection & Immunity at the UMC Utrecht. (2017-)

Coordinator of the H2020-funded project ECRAID-Base (March 2021-) and Chief Executive Officer of the ECRAID foundation (Jan 2022-)

Member of the Koninklijke Nederlandse Academie voor Wetenschappen en Kunsten (Royal Academy of Sciences and Art) (April 2021-)

Advisory boards, DSMBs and steering committees 

Chair of international study steering committee EMBRACE study, Janssen Vaccines; payments to UMC Utrecht) (2017-);

Member of Independent Data Monitoring Committee of the PSK008 and PSK009 studies on pneumococcal vaccination, Sanofi Pasteur (payments to UMC Utrecht) (2019-)

Member of Advisory Board clinical development for bactriophage therapy (international), Pherecytes (payments to Ecraid) (2022-)

Member of Advisory Board pneumococcal vaccination (international), Merck Sharp & Dohme BV (payments to UMC Utrecht) (2020-)

Scientific Advisor for Janssen Research & Devlopment for Ecraid assisting Janssen in finding study sites for E.mbrace study in European countries (all payments to Ecraid)

Editorial board member CMI Communications (2024-)

Activities ended

Member Advisory Boards (all payments to UMC Utrecht: Covid-19 treatment (national), AstraZeneca (2021); Pneumococcal vaccination (international), Pfizer (2021); Clinical development ensovibep for treatment COVID-19 (international), Novartis (2022); RS Virus (national) GSK (April 2023); Ensitrelvir (international) Shionogi (April 2023). 

Speaker fees

Takeda (Nov 2019) (payments to M. Bonten)

Expert panels

Netherlands Veterinary Medicines Institute (SDa) (2019-) (payments to UMC Utrecht).

Cluster Infectieziektenbestrijding from ZorgOnderzoek Nederland (2019-) (attendance fees to UMC Utrecht). 

Scientific Advisory Board of GARDP (Global Antibiotic Research & Development Platform (2020-) (no payments).

Advisory Panel Innovative Treatments COVID-19 of the Ministry of Health, Welfare and Sport (2020-) (attendance fees to UMC Utrecht).

Outbreak Management Team for COVID-19 (2020-) (attendance fees to UMC Utrecht)

Research activities: contract research

UMC Utrecht is a study site in the E.mbrace study; a phase 3 randomized double-blind placebo-controlled study of a 12-valent E. coli vaccine from Janssen Vaccines. Bonten is principal investigator for UMC Utrecht. (2022-) (no personal payments)

UMC Utrecht cordinates the PNEUMO study: an international observational study to quantify sero-type specific incidence of pneumococcal infections. Study sponsor: Merck. Bonten is principal investigator. (2018-) (no personal payments)

Ecraid assists Spherecytes in the execution of PhagoDAIR I: A pilot, multicenter, randomized, non-comparative, double-blind study of phage therapy in patients with hip or knee prosthetic joint infection due to Staphylococcus aureus treated with DAIR and antibiotic therapy. (no personal payments)

PI of the following studies executed by UMC Utrecht: the CAPiTA study and 3 related observational studies with PCV13 (Wyeth/Pfizer 2007-2014); HERALD study, phase3 COVID-19 vaccine (Curevac 2020-2023), VAC31518COV2001 stuyd, phase2 COVID-19 vaccine (Janssen Vaccines 2020-2022); EMPATHY study, phase2 treatment COVID19 (Novartis; 2021-2022). Payments to UMC Utrecht. (no personal payments)

Ecraid executes the phase 3 randomized double-blind placebo-ccontrolled study to ealuatve the efficacy and safety of bemnifosbuvir (ATEA pharmacuetical) in high-risk outpatients with COVID-19. (no personal payments)

Ecraid participates in the 217848 (RSV OA=ADJ-013) A phase 3 RCT to evaluate immune response of RSVPreF3 OA when co-administered with a COVID-19 mRNA vaccine. (all payments to Ecraid)

Ecraid participated in the VLA2100 COVID-19 booster vaccination study (Valneva; 2022-2023) and collaborated with Moderna (2023; influenza vaccines) and Limatech (2022-2024; Klebsiella vaccine). (all payments to Ecraid) 

Research activities: public private partnerships (PPP) funded through the Innovative Medicine Initiative (IMI)

Bonten is, on behalf of UMC Utrecht, coordinator of COMBACTE-NET, COMBACTE-CARE, COMBACTE-MAGNET en COMBACTE-CDI) with the aim to improve efficiency of clinical evaluation of new antimicrobial treatments. Collaboration in this PPP is with AstraZeneca, Pfizer, GSK, Basilea, AiCuris, DaVolterra, Janssen, Sanofi, BioMerieux and MSD (www.combacte.com). (2013-) COMBACTE CDI ended in 2021, MAGNET in 2023, CARE in 2023. (no personal payments)

Bonten is, on behalf of UMC Utrecht, co-coordinator of the PPP VITAL in which the effects of aging on vaccine response is investigated. Collaboration in this PPP is with Pfizer, GSK, Janssen, Sanofi, BioMerieux en MSD (https://vital-imi.eu/). (2017-) (no personal payments)

Bonten is, on behalf of UMC Utrecht, scientific coordinator of the PPP PrIMAVera (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance) in which the potential effects of monoclonal antibodies and vaccines on the epidemiology of antimicrobial resistance will be investigated. Collaboration in this PPP is with GSK and Janssen. (2021-) (no personal payments)

UMC Utrecht is partner in VALUE-Dx in which the effects of diagnostics in the treatment of respiratory tract infections is investigated. Collaboration in this PPP is with BioMerieux, Abbot, Janssen, BioRad en BD (https://vital-imi.eu/). Bonten co-leads the ADEQUATE study in which collaboration is with BioMerieux. (2019-) (no personal payments)

https://www.juliusclinical.com/person/marc-bonten
http://portal.juliuscentrum.nl/People/tabid/92/ctl/PeopleDetail/mid/412/StaffId/1376/UserId/0/language/nl-nl/Default.aspx
http://www.umcutrecht.nl/nl/Over-ons/Nieuws/2015/Prijs-voor-infectieziekte-deskundige

He is a VICI laureate (2006) from the Dutch Science Association, Principal Investigator of the CAPiTA study, coordinator of the EU-funded project R-GNOSIS, scientific coordinator of the IMI-funded consortiums COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET. He is member of the International Trial Steering Committee of the REMAP-CAP study, and coordinator of ECRAID-Base.  

In 2015 he received the ESCMID 2015 Award for Excellence in Clinical Microbiology and Infectious Diseases.

In 2017 he received a honorary fellowship of the Royal College of Physicians of Ireland, and was awarded the ESCMID fellowship.

In 2021 he was elected member of the Koninklijke Nederlandse Academi voor Wetenschappen.